IL-23/Th_(17)轴拮抗剂治疗中重度寻常型银屑病进展  

Research progress of biologics targeting IL-23/Th_(17) axis in the treatment of moderate-to-severe psoriasis vulgaris

作　　者：高敏 蒋晓妍 张晓艳[3] GAO Min;JIANG Xiaoyan;ZHANG Xiaoyan(Peking University China-Japan Friendship School of Clinical Medicine,Beijing 100029,China;Beijing University of ChineseMedicine,Beijing 100029,China;Department of Dermatology,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]北京大学中日友好临床医学院,北京100029 [2]北京中医药大学,北京100029 [3]中日友好医院皮肤病与性病科,北京100029

出　　处：《皮肤病与性病》2022年第3期218-221,225,共5页Dermatology and Venereology

摘　　要：IL-23/Th_(17)细胞轴在银屑病的发生发展中具有关键作用。目前,有多种靶向IL-23/Th_(17)细胞轴的生物制剂在多个国家上市并应用于银屑病的治疗。除已被广泛应用于临床的司库奇尤单抗、依奇珠单抗、乌司奴单抗等,仍有较为新兴的靶向IL-23/Th_(17)细胞轴的生物制剂不被熟知。因此本文综述4种靶向IL-23/Th_(17)细胞轴的生物制剂比美吉珠单抗、瑞沙珠单抗、泰瑞珠单抗及米吉珠单抗在治疗中重度寻常型银屑病中的疗效与安全性。IL-23/Th_(17) axis plays an important role in the occurrence and development of psoriasis.To date,several marketed biologics targeting IL-23/Th_(17) axis have been used in the treatment of psoriasis in multiple countries.In addition to secukinumab,ixekizumab and ustekinumab,which have been widely used in clinical practice,there are several emerging biologics that are not well known.Therefore,this review summarizes clinical efficacy and safety profiles of four biologics targeting IL-23/Th_(17) axis in the treatment of moderate-to-severe psoriasis vulgaris,i.e.,bimekizumab,risankizumab,tildrakizumab and mirikizumab.

关 键 词：IL-23/Th_(17)细胞轴 生物制剂 寻常型银屑病 

分 类 号：R758.63[医药卫生—皮肤病学与性病学] R751.05[医药卫生—临床医学]